| |
|
|
|
NervGen Appoints John Ruffolo To Board Of Directors, Receives Fast Track Designation For NVG-291
|
|
Vancouver, BC, October 25, 2023--NervGen Pharma, a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced the appointment of John Ruffolo, Founder and Managing Partner of Maverix Private Equity to the Company's Board of Directors. NervGen also announced that the U.S. FDA has granted Fast Track designation for its proprietary lead compound, NVG-291, in individuals with spinal cord injury.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NervGen Pharma Announces Leadership Transition
|
|
Vancouver, BC, September 23, 2022--NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Board of Directors and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & Chief Executive Officer and a member of the Board, effective immediately.
|
|
|
|
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
